10 Best Small-Cap Stocks Ready To Explode

5. Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Analyst Upside Potential: 112.18%

Neumora Therapeutics, Inc. (NASDAQ:NMRA) ranks as the 7th best small-cap stock ready to explode. Analysts’ 12-month median price target is pointing towards a 112.18% upside from current levels. It is a biopharmaceutical company focused on developing new treatments for brain diseases. It operates in the clinical stage, meaning it is working on medications that are being tested in humans to see if they are safe and effective.

The company has a pipeline of seven programs aimed at treating various neuropsychiatric disorders (like depression and schizophrenia) and neurodegenerative diseases (such as Alzheimer’s). These programs explore new ways to interact with the brain’s chemistry to improve treatment outcomes for conditions that currently have limited options.

One of their main drug candidates is navacaprant (NMRA-140), which is designed to treat major depressive disorder (MDD). This medication works by blocking specific receptors in the brain that are linked to mood regulation. During the third quarter results for fiscal 2024, Neumora Therapeutics, Inc. (NASDAQ:NMRA) announced that it is currently enrolling in the registrational Phase 3 KOASTAL program, which is designed to evaluate the efficacy and safety of navacaprant monotherapy for the treatment of MDD. Management expects topline data from the program by the end of 2024 and topline results from KOASTAL 2 and KOSTAL 3 programs during the first half of 2025.

NMRA-140 is a significant treatment for the company as it treats MDD, as per management statistics MDD is a leading cause of disability around the world, and around 280 million people suffer from the disease worldwide. NMRA-140 has the potential to reshape the treatment of depression. Neumora Therapeutics, Inc. (NASDAQ:NMRA) believes that its pipeline has the potential to reach up to 40 million patients in 2026 bringing significant revenue as it enters the commercial stage.

As of November 12, the company had $341.3 million in cash, cash equivalents, and marketable securities, which the management believes is sufficient to support operations into mid-2026.